Diakonos Oncology Corporation

This study tests a new treatment called DOC1021 for people with advanced melanoma that has not responded to standard therapies. The treatment uses a patient's own immune cells, trained to attack their specific tumor. The goal is to see if it is safe and can shrink tumors. About 3…

This study tests whether adding a new immune cell treatment (DOC1021) to standard therapy can help people with a newly diagnosed aggressive brain cancer called glioblastoma live longer. About 180 adults will be randomly assigned to receive either standard care alone or standard c…